Health Care • Biotechnology: Commercial Physical & Biological Resarch
$116.80 ▼ -0.07
(-0.06%)
MKT CAP: $23.68B • VOL: 3.05M
52W L $89 52W H $133
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$98
MEDIAN
$131
MEAN
$133
HIGH
$159
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INCY TAPE
INCY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $141.33 | $134.32 | 2025-02-14 | $106.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $147.17 | $137.82 | 2025-02-06 | $109.79 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $133.15 | $128.48 | 2025-01-29 | $112.13 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $119.14 | — | 2025-01-17 | $114.46 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $102.78 | $110.96 | 2025-01-09 | $103.95 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $138.99 | $121.47 | 2024-12-18 | $101.62 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $113.30 | $117.97 | 2024-12-04 | $108.62 | -4.3% | 48% | C |